» Articles » PMID: 28974511

TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes. Using a transgenic screen in zebrafish, thymocyte selection-associated high mobility group box protein (TOX) was uncovered as a collaborating oncogenic driver that accelerated T-ALL onset by expanding the initiating pool of transformed clones and elevating genomic instability. TOX is highly expressed in a majority of human T-ALL and is required for proliferation and continued xenograft growth in mice. Using a wide array of functional analyses, we uncovered that TOX binds directly to KU70/80 and suppresses recruitment of this complex to DNA breaks to inhibit nonhomologous end joining (NHEJ) repair. Impaired NHEJ is well known to cause genomic instability, including development of T-cell malignancies in KU70- and KU80-deficient mice. Collectively, our work has uncovered important roles for TOX in regulating NHEJ by elevating genomic instability during leukemia initiation and sustaining leukemic cell proliferation following transformation. TOX is an HMG box-containing protein that has important roles in T-ALL initiation and maintenance. TOX inhibits the recruitment of KU70/KU80 to DNA breaks, thereby inhibiting NHEJ repair. Thus, TOX is likely a dominant oncogenic driver in a large fraction of human T-ALL and enhances genomic instability. .

Citing Articles

Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage.

Liu M, Li Y, Deng Z, Zhang K, Huang S, Xia J Cell Death Dis. 2025; 16(1):84.

PMID: 39929806 PMC: 11811017. DOI: 10.1038/s41419-025-07392-8.


BCAT1 Associates with DNA Repair Proteins KU70 and KU80 and Contributes to Regulate DNA Repair in T-Cell Acute Lymphoblastic Leukemia (T-ALL).

Tosello V, Rompietti C, Papathanassiu A, Arrigoni G, Piovan E Int J Mol Sci. 2025; 25(24.

PMID: 39769333 PMC: 11676169. DOI: 10.3390/ijms252413571.


Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.

Chen Y, Yin Z, Westover K, Zhou Z, Shu L Mol Cancer Ther. 2024; 24(1):33-46.

PMID: 39404173 PMC: 11694067. DOI: 10.1158/1535-7163.MCT-24-0504.


TOX2 nuclear-cytosol translocation is linked to leukemogenesis of acute T-cell leukemia by repressing TIM3 transcription.

Li A, Zhang J, Zhan L, Liu X, Zeng X, Zhu Q Cell Death Differ. 2024; 31(11):1506-1518.

PMID: 39080376 PMC: 11519604. DOI: 10.1038/s41418-024-01352-z.


Rare Drivers at Low Prevalence with High Cancer Effects in T-Cell and B-Cell Pediatric Acute Lymphoblastic Leukemia.

Mandell J, Diviti S, Xu M, Townsend J Int J Mol Sci. 2024; 25(12).

PMID: 38928295 PMC: 11203805. DOI: 10.3390/ijms25126589.


References
1.
Huang Y, Su M, Jiang X, Zhou Y . Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma. Blood. 2014; 125(9):1435-43. DOI: 10.1182/blood-2014-05-571778. View

2.
Yuan F, Gu L, Guo S, Wang C, Li G . Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem. 2004; 279(20):20935-40. DOI: 10.1074/jbc.M401931200. View

3.
Hnisz D, Abraham B, Lee T, Lau A, Saint-Andre V, Sigova A . Super-enhancers in the control of cell identity and disease. Cell. 2013; 155(4):934-47. PMC: 3841062. DOI: 10.1016/j.cell.2013.09.053. View

4.
Tessema M, Yingling C, Grimes M, Thomas C, Liu Y, Leng S . Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PLoS One. 2012; 7(4):e34850. PMC: 3319602. DOI: 10.1371/journal.pone.0034850. View

5.
Mansour M, Abraham B, Anders L, Berezovskaya A, Gutierrez A, Durbin A . Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014; 346(6215):1373-7. PMC: 4720521. DOI: 10.1126/science.1259037. View